Skip to main content
Addgene

pLV-dCas9-p300-P2A-PuroR
(Plasmid #83889)

Ordering

This material is available to academics and nonprofits only.
Item Catalog # Description Quantity Price (USD)
Plasmid 83889 Standard format: Plasmid sent in bacteria as agar stab 1 $85

Backbone

  • Vector backbone
    lentiCRISPR v2
  • Backbone size w/o insert (bp) 7800
  • Total vector size (bp) 14538
  • Vector type
    Mammalian Expression, Lentiviral, CRISPR
  • Selectable markers
    Puromycin

Growth in Bacteria

  • Bacterial Resistance(s)
    Ampicillin, 100 μg/mL
  • Growth Temperature
    37°C
  • Growth Strain(s)
    NEB Stable
  • Copy number
    Unknown

Gene/Insert 1

  • Gene/Insert name
    S.pyogenes dCas9 with c-terminal human p300 Core effector fusion (aa 1048-1664 of human p300)
  • Species
    H. sapiens (human), Synthetic; S. pyogenes
  • Insert Size (bp)
    6138
  • Mutation
    D10A; H840A in S.pyogenes Cas9
  • GenBank ID
    WP_010922251.1 NP_001420.2
  • Entrez Gene
    EP300 (a.k.a. KAT3B, MKHK2, RSTS2, p300)
  • Promoter EFS
  • Tags / Fusion Proteins
    • nucleoplasmin NLS (C terminal on insert)
    • Flag (C terminal on insert)

Cloning Information for Gene/Insert 1

Gene/Insert 2

  • Gene/Insert name
    pac from Streptomyces alboniger
  • Alt name
    puromycin N-acetyltransferase
  • Species
    Streptomyces alboniger
  • Insert Size (bp)
    597

Resource Information

Terms and Licenses

  • Academic/Nonprofit Terms
  • Industry Terms
    • Not Available to Industry
Trademarks:
  • Zeocin® is an InvivoGen trademark.
How to cite this plasmid ( Back to top)

These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.

  • For your Materials & Methods section:

    pLV-dCas9-p300-P2A-PuroR was a gift from Charles Gersbach (Addgene plasmid # 83889 ; http://n2t.net/addgene:83889 ; RRID:Addgene_83889)
  • For your References section:

    CRISPR-Cas9 epigenome editing enables high-throughput screening for functional regulatory elements in the human genome. Klann TS, Black JB, Chellappan M, Safi A, Song L, Hilton IB, Crawford GE, Reddy TE, Gersbach CA. Nat Biotechnol. 2017 Apr 3. doi: 10.1038/nbt.3853. 10.1038/nbt.3853 PubMed 28369033